Aureon Laboratories Introduces Prostate Px(R)+, First Biopsy-Based Test to Predict Prostate Cancer Disease Progression and Recurrence
5/19/2008 8:54:12 AM
YONKERS, N.Y.--(BUSINESS WIRE)--Aureon Laboratories, Inc., a specialized laboratory dedicated to advancing personalized cancer treatment through predictive pathology, today announced the introduction of Prostate Px®+, the first commercial test to predict prostate cancer progression and disease recurrence at the time of diagnosis. The announcement was made at the American Urological Association Annual Meeting, now underway at the Orange County Convention Center in Orlando (Booth# 505).
comments powered by